| Name | Title | Contact Details |
|---|---|---|
Chris Ceresini |
VP of Finance and HR | Profile |
CrunchTime! Information Systems, Inc., a Battery Ventures company, provides a comprehensive restaurant back office solution that simplifies and automates food and labor operations. By driving the flow of information throughout the organization, CrunchTime! ensures operators make timely, fact-based decisions that help brands reduce food and beverage costs, drive labor efficiencies, and better manage the quality and consistency of their foodservice operations. For over 25 years, CrunchTime! has enabled restaurant chains of all sizes to scale efficiently and save money.
CAE Solutions Corp. is a Burlington, MA-based company in the Software and Internet sector.
BullsEye Computing Solutions is a Ellicott City, MD-based company in the Software and Internet sector.
Sopheon partners with customers to provide complete Enterprise Innovation Management (EIM) solutions including software, expertise, and best practices. We have operating bases in the United States, the United Kingdom, the Netherlands and Germany, with distribution, implementation and support channels worldwide. Sopheon (LSE: SPE) is listed on the AIM Market of the London Stock Exchange.
Cypher Genomics is a leading genome informatics company offering a highly accurate, rapid and robust interpretation software solution for users of human genome sequencing. The proprietary, automated genomic interpretation platform allows clinical laboratories to tune Cypher Genomics' market leading sensitivity and specificity profiles to develop molecular tests for diagnostic and prognostic use, and pharmaceutical companies to discover biomarkers from whole genome sequence data in sample sizes typical of early stage drug development studies. Through Mantis™, the genome interpretation software as a service offering, and Coral™, a biomarker discovery service, Cypher Genomics can improve health care and reduce costs by facilitating improved diagnostic accuracy and earlier interventions, optimizing therapeutic approaches and reducing adverse drug reactions. The gap between the ability to generate whole genome sequences at scale and the primarily manual process of interpretation to date creates a significant unmet need that is well served by the Cypher Genomics solution.